Effects of 5-fluorouracil on human mitogen-activated peripheral blood lymphocytes from healthy individuals

Anticancer Research

Volumn 28, Issue 6 A, 2008, Pages 3785-3791

  Eisenthal, Avi ^a,b   Eytan, Karin ^a   Brazowski, Eli ^a   Katz, Ben Zion ^a   Shirazi, Idit ^a   Skornick, Yehuda ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

5 fluorouracil; Activation; Lymphocytes

Indexed keywords

CD4 ANTIGEN; CYCLOPHOSPHAMIDE; DNA; DOXORUBICIN; FLUOROURACIL; GAMMA INTERFERON; INTERLEUKIN 10; MERCAPTOPURINE;

ARTICLE; CD4+ T LYMPHOCYTE; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOKINE RELEASE; DNA SYNTHESIS; DRUG DOSE INCREASE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

EID: 58149150058     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Eisenthal A, Barbarsteyn E, Gitstein G and Lifschitz-Mercer B: Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear (PBMC) adherent cells culture. Cancer Invest 24: 28-34, 2006.
2. Baxevanis CN, Tsavaris NB, Papadhimitriou SI, Zarkadis IK, Papadopoulos NG, Bastounis EA and Papamichail M: Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumors receiving second-line chemotherapy: correlation with clinical responses. Eur J Cancer 33: 1202-1208, 1997.
3. Aballea S, Chancellor JV, Raikou M, Drummond MF, Weinstein MC, Jourdan S and Bridgewater J: Cost-effectiveness analysis of oxiliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer 109: 1082-1089, 2007.
4. Sohn KJ, Croxford R, Yates Z, Lucock M and Kim YI: Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. J Natl Cancer Inst 96: 134-144, 2004.
5. Tong D, Poot M, Hu D and Oda D: 5-Fluorouracil-induced apoptosis in cultured oral cancer cells. Oral Oncol 36: 236-241, 2000.
6. Engelbrecht C, Ljungquist I, Lewan L, Yngner T: Modulation of 5-fluorouracil metabolism by thymidine. In vivo and in vitro studies on RNA-directed effects in rat liver and hepatoma. Biochem Pharmacol 33: 745-750, 1984.
7. Longley DB, Boyer J, Allen WL, Latif T, Ferguson PR, Maxwell PJ, McDermott U, Lynch M, Harkin DP and Johnston PG: The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res 62: 2644-2649, 2002.
8. Longley DB, Ferguson PR, Boyer J, Latif T, Lynch M, Maxwell P, Harkin DP and Johnston PG: Characterization of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS- and non-TS-targeted chemotherapies. Clin Cancer Res 7: 3533-3539, 2001.
9. Lothstein L, Suttle DP, Roaten JB, Koseki Y, Israel M and Sweatman TW: Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288). Biochem Pharmacol 60: 1621-1628, 2000.
10. Colvin OM: An overview of cyclophosphamide development and clinical applications. Curr Pharm Des 5: 555-560, 1999.
11. Whiteside TL, Heo DS, Takagi S and Herberman RB: Characterization of novel antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes. Transplant Proc 20: 347-350, 1988.
12. Hilders CG, Ras L, van-Eendenburg JD, Nooyen Y and Fleuren GJ: Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma. Int J Cancer 57: 805-813, 1994.
13. Okamoto M, Kasetan H, Kaji R, Goda H, Ohe G, Yoshida H and Sato M: Cis-diaminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro. Cancer Immunol Immunother 47: 233-241, 1998.
14. Reiter Z, Ozes ON, Blatt LM and Taylor MW: A dual antitumor effect of a combination of interferon-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity. Clin Immunol Immunopathol 62: 103-111, 1992.
15. Meurette O, Fontaine A, Rebillard A, Le-Moigne G, LamyT, Lagadic-Gossmann D and Dimanche-Boitrel MT: Cytotoxicity of TRAIL/anticancer drug combinations in human normal cells. Ann NY Acad Sci 1090: 209-216, 2006.
16. Brazowski E, Eytan K and Eisenthal A: In vitro modulation of interleukin-2-mediated human peripheral mononuclear cell proliferation and antitumor cytotoxicity by 5-fluorouracil. Anticancer Res 27: 4135-4142, 2007.
17. Zhu Z, Fu Q, Nightingale CH, Zhao YP, Liao Q and Li DK: Penetration kinetics of 5-fluorouracil into pancreatic fluid in post pancreatoduodenectomy patients. Anticancer Drugs 9: 685-688, 1998.
18. Gołb J, Zagozdzon R, Kaminski R, Kozar K, Gryska K, Izycki D, Mackiewicz A, Stoklosa T, Giermasz A, Lasek W and Jacobisiak M: Potentiated antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo. Leukemia 15: 613-620, 2001.
19. Onocera H, Somers SS and Guillou PJ: Paradoxical effects of 5-FU/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer. Br J Cancer 62: 1042-1046, 1990.
20. Ehrnrooth E, Sorensen B, Poulsen JH, Sorensen BS and von der Maase H: Changes in thymidylate synthase mRNA in blood leukocytes from patients with colorectal cancer after bolus administration of 5-fluorouracil. Acta Oncol 39: 53-57, 2000.
21. Eisenthal A, Barbarsteyn E, Gitstein G and Lifschitz-Mercer B: Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear (PBMC) adherent cell culture. Cancer Invest 24: 28-34, 2006.
22. 18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 29: 1462-1469, 2002.
23. Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T and Hashimoto-Tamaoki T: Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 61: 1029-1037, 2001.
24. Tokunaga E, Oda S, Fukushima M, Maehara Y and Sugimachi K: Differential growth inhibition by 5-fluorouracil in human colorectal carcinoma cell lines. Eur J Cancer 36: 1998-2006, 2000.
25. Sheldon PJ and Holborow EJ: Human erythrocyte rosette formation with mitogen-stimulated human lymphocytes - A marker for the demonstration of activated T-cells. J Immunol Methods 7: 379-386, 1975.
26. Sasaki M, Sekizawa T, Takahashi H, Abo T and Kumagai K: Heterogeneity of human T lymphocytes to bind sheep erythrocytes and mitogenic responses of their subpopulations. J Immunol 115: 1509-1514, 1975.
27. Gobec S, Sollner-Dolenc M, Urleb U, Wraber B, Simcic S and Filipic M: Modulation of cytokine production by some phthalimido-desmuramyl dipeptides and their cytotoxicity. Farmaco 59: 345-352, 2004.
28. Weiner HL: Immunosuppressive treatment in multiple sclerosis. J Neurol Sci 223: 1-11, 2004.
29. Kast RE: Ribavirin in cancer immunotherapies: controlling nitric oxide augments cytotoxic lymphocyte function. Neoplasia 5: 3-8, 2003.
30. Dzialo Hatton R, Milbrandt J, Hockett RD Jr and Weaver CT: Differential expression of Fas ligand in Th1 and Th2 cells is regulated by early growth response gene and NF-AT family members. J Immunol 166: 4534-4542, 2001.
31. Roozendaal R, Vellenga E, de-Jong MA, Traanberg KF, Postma DS, de-Monchy JG and Kauffman HF: Resistance of activated human Th2 cells to NO-induced apoptosis is mediated by gamma-glutamyltranspeptidase. Int Immunol 13: 519-528, 2001.